Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: HandsOn who wrote (756)	5/16/1999 12:30:00 AM
From: StockMiser	Read Replies (1) \| Respond to of 2344

I'm doing this from memory so bear with. I seem to recall insitutional ownership going from about 6% late last year, to about 14% earlier this year. At this point it's still fairly small, though rising. As for the Friday's action (someone else had asked), the Streetq rumor didn't seem to appear till almost market close. A lot of traders play these conferences for the early rise going into them and many sold earlier in the day assuming it was the peak. A good strategy for many biotechs at this conference. As for BIOM, I don't think anyone counted on the PR's to be this good (they were worded exceptionally well), or were sure about any mass media exposure. One thing I would like to comment on is this theory of "the news if factored in", or "they were already expecting this news". That bit of trading cliche works if the news is actually "out". These Theratope studies were deeply hidden in scientific journals. If you recall the Entremed article in the NY Times that sent it from $9 to $84 in one day - there was absolutely not a single piece of new information that wasn't already known by EVERYONE that followed the stock, and by EVERYONE that followed cancer research. The article appeared in summer of 1998 and was based on findings that had been out, published, press released, and thoroughly analyzed about 6 months earlier. The ONLY difference was the level of media exposure. ENMD at $84 was not a single day closer to finding a cure than they were the day prior when they were selling at $9. The fact is, Biomira is a pure, unadulterated, under-hyped, under-exposed, diamond of a biotech. We are well past the mouse studies, we've made our corporate alliances, and we're now in the home stretch. In a couple years, Biomira will be valued like all the other biotechs that make money - and they will be worth $40-100 in short time. This will happen regardless of NY Times, Barrons, or WSJ hype. Now, on a personal level, I'd love to see our little gem graduate like ENMD, GERN, or IMCL - all previously unknown little companies quietly working on changing how we think about disease and treament. Nothing wrong with letting the world in early on our little secret - if they don't discover us now, they will later. SM